Patent application number | Description | Published |
20080319040 | N-Acylic Aminoacid Derivatives, Method For The Production Thereof, Pharmacological Composition And The Use In The Form Anti-Allergic, Anti-Inflammatory And Hypolipidemic Agents - The present invention relates to N-acyl derivatives of amino acids and pharmaceutically acceptable salts thereof | 12-25-2008 |
20090111874 | Phenyl-containing n-acyl amine and aminoacid derivatives, methods for the production thereof, a pharmaceutical composition and the use thereof - The present invention relates to novel phenyl-N-acyl derivatives of biogenic amines and amino acids of general formula (I) as cyclooxynease inhibitors, possessing analgetic and anti-inflammatory properties and devoid of side effects in particular ulcerogeneity and pro-spasmodic actions, as well as capability to potentiate effect of other analgetics, and possessing in addition antihypoxic, antidepressant and anti-Parkinsonistic action; as well as to the processes for the preparation novel and known phenyl-N-acyl derivatives of biogenic amines, to a pharmaceutical composition and to an agent comprising compounds of general formula (I) as well as to use thereof and a method of treating. | 04-30-2009 |
20100267962 | N-ACYLIC AMINOACID DERIVATIVES, METHOD FOR THE PRODUCTION THEREOF, PHARMACOLOGICAL COMPOSITION AND THE USE IN THE FORM ANTI-ALLERGIC, ANTI-INFLAMMATORY AND HYPOLIPIDEMIC AGENTS - The present invention relates to N-acyl derivatives of amino acids and pharmaceutically acceptable salts thereof | 10-21-2010 |
20110224213 | Use of Glutaric Acid Derivatives or the Pharmaceutically Acceptable Salts Thereof as Anti-Arrhythmic Agents - The invention relates to the use of glutaric acid derivatives of general formula (I), which are disclosed in the invention description, as anti-arrhythmic agents. | 09-15-2011 |
20120129908 | Agent For The Prophylaxis And Treatment Of Highly Pathogenic Infectious Diseases - The invention relates to an agent for the treatment and/or prophylaxis of highly pathogenic infectious diseases, such as highly pathogenic influenza A (in particular, subtypes H5 and H7) and severe acute respirator syndrome caused by the genotype IV coronavirus. The agent is in the form of glutaryl histamine or a pharmaceutically acceptable salt thereof. The invention also relates to a pharmaceutical composition based on glutaryl histamine or a pharmaceutically acceptable salt thereof and to a method for the treatment and/or prophylaxis of highly pathogenic infectious diseases. | 05-24-2012 |
20120264724 | ANTIMICROBIAL AGENTS BASED ON HEMIN DERIVATIVES - The invention relates to novel antimicrobial, including antibacterial and antifungal, agents and compositions based on hemin derivatives of general formula (I), and also to the production of novel hemin derivatives. The advantages of antibacterial agents based on hemin derivatives are their biocompatibility, biodegradability, high effectiveness against resistant bacteria and widespread microfungi that are harmful to humans, and freedom from toxicity and side effects. | 10-18-2012 |
20130109880 | PHENYL-N-ACYL DERIVATIVES OF AMINES AND AMINO ACIDS, A PROCESS FOR THE PREPARATION THEREOF, A PHARMACEUTICAL COMPOSITION AND USE THEREOF | 05-02-2013 |
20130324540 | USE OF GLUTARIC ACID DERIVATIVES OR THE PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF AS ANTI-ARRHYTHMIC AGENTS - The invention relates to the use of glutaric acid derivatives of general formula (I), which are disclosed in the invention description, as anti-arrhythmic agents. | 12-05-2013 |
20150031854 | Novel Derivatives of Hemin with Antibacterial and Antiviral Activity - The invention relates to novel hemin derivatives of general formula (I), preparing and use thereof as antibacterial and/or antiviral agents, including, as a component in a pharmaceutical compositions. Advantages of the novel antibacterial and antiviral agents based on the hemin derivatives are in their biocompatibility, biodegradability, a high efficacy against resistant bacteria and widespread viruses which are dangerous to humans, and the lack of toxicity. | 01-29-2015 |